Elanco Animal Health reported QQ3 2025 revenue of $1.137 billion, up 10.39% year over year but down 8.38% quarter over quarter. The company delivered a gross profit of $607 million and a gross margin of 53.4%, reflecting a solid core profit pool, yet operating profitability remained modest with an operating income of $27 million and EBITDA of $178 million (EBITDA margin roughly 15.7%). Net income was negative at $34 million, producing an EPS of −$0.07 for the quarter, driven by elevated operating expenses and other charges. Depreciation and amortization were substantial at $176 million, contributing to a high cost of expenses base (cost and expenses of $1.11 billion) and a pretax loss of $50 million despite positive operating earnings. These dynamics imply a top-line expansion supported by volume or mix, but profitability is constrained by non-cash depreciation, interest costs, and other non-operating items. Management commentary (when available) would be critical to understanding the durability of revenue growth and margin normalization as the company progresses through its strategic initiatives.